How To Keep Academic/Big Pharma Alliances from Going off the Rails

The Dana-Farber Cancer Institute in Boston made headlines earlier this month after siding with Novartis in a brewing legal battle with a Dana-Farber spinout, Gatekeeper Pharmaceuticals. The disagreement stems from both companies claiming they are the rightful licensees of certain intellectual property (IP) created by Dana-Farber researchers. The IP, originally committed to Gatekeeper via an … Continue reading “How To Keep Academic/Big Pharma Alliances from Going off the Rails”